Lupin receives US FDA approval for sacubitril and valsartan tablets: Our Bureau, Mumbai Friday, January 24, 2025, 15:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) announc ...

Lupin has received tentative approval from the USFDA to market a generic HIV drug in the US under PEPFAR. The drug, made at ...

Lupin receives US FDA marketing nod for generic Triumeq PD tablets for oral suspension to trteat HIV-1 infection: Our Bureau, Mumbai Friday, January 24, 2025, 14:15 Hrs [IST] Glob ...

recently prevailed against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin) in a patent infringement suit brought in the District of Delaware. After a three-day bench trial, the court found that ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Today’s stock recommendations feature a mix of picks from the pharmaceutical, insurance, and chemicals sectors.

Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S. (IQVIA MAT November 2024) ...

Lupin: Pharmaceutical company Lupin received an Establishment Inspection Report (EIR) from the US FDA for its Pithampur Unit-1 facility, which manufactures APIs and finished products. The EIR, ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. According to the company ...

The Pharma sector outperformed in 2024, gaining 29%, driven by resilience to macro challenges, US FDA resolutions, and ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...